More news about PB&B

PB&B receives an additional CHF 1 M equity investment

18.07.2017 10:45
PB&B Facial Volumizer

Medtech startup PB&B has received an additional CHF 1 million equity investment from its strategic investor. This investment will be allocated to launching the first-in-human clinical trial in 2018 for volume restauration of aging midface.

Last year, PB&B received equity investment of CHF 2M from its Chinese strategic investor. Today, the company has, yet again, received an additional CHF 1 M to facilitate its upcoming clinical trial.

PB&B is an active player in the field of medical aesthetics. The startup is focusing on making Aesthetics and Plastic Surgery procedures natural and minimally invasive. Since establishment, the startup has positioned itself as a novel soft tissue remodelling injection in the market of fillers and fat transfer procedures, through implementation of a market entry strategy directed towards anti-aging and facial rejuvenation of the mid-facial areas.

The “PB&B Technology” uses biodegradable microspheres loaded with lipid molecules, which are injected under the skin for a controlled release and increase of fat tissue volume. As a result, the process directs the patient's own tissues to naturally rejuvenate the face and diminish any wrinkles for a period of up to 20 months on average; longer than with any dermal filler.

About PB&B
PB&B SA was founded in 2013 in Lausanne by a group of bioengineers who have developed their technology and products with Swiss academic institutes, plastic surgeons and international firms. Their passion for Aesthetics has enabled them to win a number of awards including Venture Kick, HUG Innovation Trophy 2014 and they have also been nominated in several others internationally.


Please login or
register to comment

Please login or sign up to comment. Commenting guidelines


A showcase for female CEOs

Startupticker has recorded Swiss start-ups with female CEOs and ranked them by sector. The map which includes links to 80+ companies can be downloaded in our article.



By continuing to use this website you agree with our TERMS AND CONDITIONS